Is ILMN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Illumina (ILMN) rests on Installed base and the consumables annuity: Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. The bear case rests on competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. Analysts covering it publish targets from $113.00 to $365.00 against a $262.54 price, so even the professionals disagree by 105% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen. Illumina's recent history was dominated by its acquisition of cancer-screening company GRAIL and the regulatory fight that followed. Antitrust authorities in the US and Europe challenged the deal, the European Commission ordered a divestiture in 2023, and Illumina distributed about 85.5% of GRAIL to its shareholders in June 2024, separating the two companies. In September 2024 the European Court of Justice annulled the Commission's jurisdiction over the original review, and Illumina avoided a 432 million euro fine. With GRAIL gone, management has refocused the company on its core sequencing platforms, consumables growth, multiomics, and operating-margin recovery. In 2026 the story has been one of steady beats and a sharply higher share price. Revenue reached about $1.16 billion in the second quarter of 2026, with adjusted EPS of $1.31 against a $1.23 consensus, the fourth consecutive quarter ahead of estimates. In October 2026 Illumina launched BioInsight, its first unified software environment for genomic and multiomic analysis, alongside AI tools such as its SpliceAI2 model, and announced a $1 billion commercial paper program. An FDA recall listing also appeared for an earlier server correction on the NovaSeq 6000Dx clinical instrument.
The bull case: what would have to be true for $365.00
The most optimistic published target on ILMN is $365.00, +39.0% from the $262.54 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Installed base and the consumables annuity.
Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. Sequencing consumables revenue was about $755 million in the fourth quarter of 2025, up 8% year over year and roughly 11% excluding China. As long as customers keep running these machines, consumables provide a relatively sticky, high-visibility revenue stream.
2. The NovaSeq X transition.
The high-throughput NovaSeq X drives lower cost per genome and higher consumables volume as it replaces older systems. Illumina reported the installed base reaching roughly 890 instruments by the end of 2025, with the research transition nearly complete and clinical conversion past two-thirds. Each placement seeds future consumables demand, so the pace of conversion matters to the growth story.
3. Multiomics and clinical diagnostics.
Beyond DNA sequencing, Illumina is expanding into proteomics, single-cell, and spatial methods, and is leaning into clinical applications such as comprehensive genomic profiling in oncology and whole-genome sequencing in genetic disease. Clinical consumables excluding China grew about 20% in the fourth quarter of 2025, a faster-growing mix the company is trying to enlarge.
4. Margin recovery.
After the GRAIL distraction and a cost-reduction program, Illumina is targeting improved profitability. For fiscal 2026 it guided to a non-GAAP operating margin in roughly the 23.3% to 23.5% range, and its trailing twelve month GAAP operating margin stood near 21% by mid 2026, with gross margin near 68% and net margin near 18%. Continued margin expansion is a key part of how the company frames its earnings recovery.
5. Software and AI on top of the sequencer.
Illumina is trying to capture more of the analysis that happens after sequencing. In October 2026 it launched the BioInsight Platform, described as its first unified software environment for genomic and multiomic research, and expanded AI tools including the SpliceAI2 model for interpreting genetic variants. Software revenue is small next to consumables, but it ties customers more closely to the Illumina workflow.
The bear case: what would have to be true for $113.00
The most pessimistic published target is $113.00, -57.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Illumina is worth if the risks below bite instead of the drivers above.
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ILMN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ILMN
20 analysts cover ILMN, with an average target of $241.05 (-8.2% against $262.54) and a split of 11 buy, 6 hold, 4 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ILMN forecast and price target page.
How is ILMN valued? (as of October 2026)
Snapshot for ILMN as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year
- 2026 revenue consensus: ~$4.62 billion (~11% growth); 2027 consensus ~$4.92 billion
- Margins (TTM): Gross ~68%, operating ~21%, net ~18%
- Net income and EPS (TTM): ~$824 million net income; EPS ~$5.39 trailing, ~$6.12 forward
- P/E: ~48x trailing, ~43x forward
- Market cap: ~$39 billion at $260.52 (16 October 2026)
- Dividend: None
- Cash and debt: ~$1.17 billion cash, ~$2.53 billion debt; ~$0.8 billion TTM free cash flow
Illumina's multiple has expanded far faster than its earnings: the shares are up about 94% year to date and 172% over a year, while consensus calls for 2026 revenue growth near 11% and EPS of about $5.36. At roughly 43 times forward earnings and 36 times EV/EBITDA, the price assumes growth and margin expansion continue well beyond 2026, and the stock sits above the $241 average analyst target even as individual targets, such as JPMorgan's move to $320, have risen.
How do you decide if ILMN is a buy?
Rather than asking whether ILMN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ILMN indirectly through an index or sector ETF before adding more.
What would change your mind on ILMN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Installed base and the consumables annuity stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ILMN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ILMN against your real portfolio and see your actual exposure before deciding.
Investing in Illumina with AI
Connect the broker you already use and ask Walnut's AI how ILMN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ILMN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Installed base and the consumables annuity, with revenue (ttm) at ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year. The bear case rests on competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. Analysts covering it are spread from $113.00 to $365.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ILMN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $113.00, -57.0% from the $262.54 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ILMN?
+
Installed base and the consumables annuity. Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. The most optimistic analyst target on ILMN is $365.00, +39.0% from the $262.54 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ILMN?
+
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure. The most pessimistic published target is $113.00, -57.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Illumina do?
+
Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers.
What would have to change for ILMN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Installed base and the consumables annuity) stalling in the reported numbers rather than in the narrative, the risk above (competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Illumina do?
+
Illumina makes next-generation DNA sequencing systems and the consumables that run on them, used in genomics research, clinical diagnostics, and applied markets. It follows a razor-and-blades model: instruments such as the NovaSeq X, NextSeq, and MiSeq seed an installed base, and most revenue comes from recurring reagents and flow cells. The company is also expanding into multiomics.
What is Illumina's (ILMN) ticker symbol?
+
ILMN, listed on Nasdaq. Officially Illumina, Inc., headquartered in San Diego, California, and founded in 1998. It is a constituent of the S&P 500 and Nasdaq-100 and trades during US market hours at every major US brokerage, where you can buy whole or fractional shares.
What happened with Illumina and GRAIL?
+
Illumina acquired cancer-screening company GRAIL, but antitrust regulators in the US and Europe challenged the deal. The European Commission ordered a divestiture, and Illumina distributed about 85.5% of GRAIL to shareholders in June 2024. In September 2024 the European Court of Justice annulled the Commission's jurisdiction, and Illumina avoided a 432 million euro fine.
Walnut is informational, not investment advice, and gives no verdict on ILMN. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.